Challenges and New Directions in Obesity Management: Lifestyle Modification Programmes, Pharmacotherapy and Bariatric Surgery

Abstract

Obesity is a growing health problem worldwide, and it is associated with serious medical and psychosocial comorbidities, impairment of health-related quality of life (HRQoL) and an increased risk of mortality. This article aims to discuss challenges faced by health-care providers when managing patients with obesity and to highlight sustainable policies in clinical practice and future research. All health professionals dealing with obesity should consider lifestyle-modification programmes within a multidisciplinary setting as the key element of weight management. However, standardisation is needed in terms of nature, content and duration of these programmes in order to facilitate their implementation in clinical practice at different levels. Moreover, health professionals should be aware that these programmes, for patients indicating "non-response," can be combined with recently approved anti-obesity drugs such as liraglutide, naltrexone/bupropion, lorcaserin and phentermine/topiramate, as well as with relatively less invasive bariatric surgery techniques such as Lap Band, endoscopic sleeve gastroplasty and gastric bypass. In any case, neither anti-obesity medication nor bariatric surgery should be considered as a miracle treatment in itself. At the same time, the field of obesity is still lacking in literature on some hot topics that need further investigation, including (i) a new phenotype termed sarcopenic obesity, to clarify its definition, potential health consequences and eventual treatment if necessary; (ii) issues that go beyond body weight, for instance, HRQoL that has been poorly studied in some populations affected by obesity; and (iii) the long-term effect of sleeve gastrectomy technique, which is becoming the most

Mobile Apps for Weight Management: A Review of the Latest Evidence to Inform Practice

“…In 2016, ~39% (1.9 billion people) of the adult population was overweight, including 13% (650 million) being obese ( 2 ). This population are at a high risk of many associated comorbidities including type 2 diabetes, cardiovascular disease, fatty liver disease, obstructive sleep apnoea, musculoskeletal disorders (such as osteoarthritis) as well as certain types of cancer ( 2 ) leading to reduced quality of life ( 3 ). This increases both the complexity and the immediate need for effective weight management.…”

Association Between Reduced Daily Steps and Sarcopenic Obesity in Treatment-Seeking Adults With Obesity

“…A new phenotype has been identified, which occurs in the presence of both sarcopenia and obesity, and is termed sarcopenic obesity (SO), describing the coexistence of increased body-fat mass deposition and a reduction in lean mass as well as muscle strength (1,2). Understanding of this condition is now becoming a scientific and clinical priority (1).…”

Lifetime Weight Cycling and Central Fat Distribution in Females With Obesity: A Brief Report

“…Obesity is defined as increased fat mass in the adipose tissue [1] and it is becoming a rising health problem worldwide [2]. Global prevalence has nearly doubled in more than 70 countries and its prevalence is continuously increasing in many others [3], to the extent that it has tripled in some developing and middle-income countries since the early 1980s [3].…”